If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic. For questions, please call (614) 722-5321.

Submitted tumor sample must contain at least 10% tumor based on Nationwide Children's Laboratory internal pathology review. Please send frozen samples (e.g. snap-frozen tissue or OCT-embedded tissue) buried in adequate amount of dry ice and ship by overnight courier. Formalin-fixed paraffin-embedded (FFPE) tissue block and FFPE tissue scrolls can be transported at room temperature.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

This test is a targeted RT-PCR analysis used to confirm the presence of a specific gene fusion (translocation) in a tumor sample that was previously identified by a research testing or by testing performed by another clinical laboratory. If a gene fusion is detected by this RT-PCR assay, a Sanger sequencing of PCR product will be performed to confirm the presence of gene fusion in the submitted sample.

This test is only available as a CONFIRMATORY TEST and only offered to patients who have a known gene fusion detected by previous research or clinical testing. If patient does not have a previously detected gene fusion, then this test cannot be ordered and sample will be rejected.

Please submit a copy of the previous tumor fusion test result, if available.

This test is a qualitative test that can test for the presence or absence of gene fusion previously identified in the patient. This test is not a qualitative test, will not be able to report what % of the sample harbors the gene fusion, and is not a test for Minimal Residual Disease (MRD). 

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic. For questions, please call (614) 722-5321.

Submitted tumor sample must contain at least 10% tumor based on Nationwide Children's Laboratory internal pathology review. Please send frozen samples (e.g. snap-frozen tissue or OCT-embedded tissue) buried in adequate amount of dry ice and ship by overnight courier. Formalin-fixed paraffin-embedded (FFPE) tissue block and FFPE tissue scrolls can be transported at room temperature.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

This test is a targeted RT-PCR analysis used to confirm the presence of a specific gene fusion (translocation) in a tumor sample that was previously identified by a research testing or by testing performed by another clinical laboratory. If a gene fusion is detected by this RT-PCR assay, a Sanger sequencing of PCR product will be performed to confirm the presence of gene fusion in the submitted sample.

This test is only available as a CONFIRMATORY TEST and only offered to patients who have a known gene fusion detected by previous research or clinical testing. If patient does not have a previously detected gene fusion, then this test cannot be ordered and sample will be rejected.

Please submit a copy of the previous tumor fusion test result, if available.

This test is a qualitative test that can test for the presence or absence of gene fusion previously identified in the patient. This test is not a qualitative test, will not be able to report what % of the sample harbors the gene fusion, and is not a test for Minimal Residual Disease (MRD). 

This test is a targeted RT-PCR analysis used to confirm the presence of a specific gene fusion (translocation) in a tumor sample that was previously identified by a research testing or by testing performed by another clinical laboratory. If a gene fusion is detected by this RT-PCR assay, a Sanger sequencing of PCR product will be performed to confirm the presence of gene fusion in the submitted sample.

This test is only available as a CONFIRMATORY TEST and only offered to patients who have a known gene fusion detected by previous research or clinical testing. If patient does not have a previously detected gene fusion, then this test cannot be ordered and sample will be rejected.

Please submit a copy of the previous tumor fusion test result, if available.

This test is a qualitative test that can test for the presence or absence of gene fusion previously identified in the patient. This test is not a qualitative test, will not be able to report what % of the sample harbors the gene fusion, and is not a test for Minimal Residual Disease (MRD). 

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic. For questions, please call (614) 722-5321.

Submitted tumor sample must contain at least 10% tumor based on Nationwide Children's Laboratory internal pathology review. Please send frozen samples (e.g. snap-frozen tissue or OCT-embedded tissue) buried in adequate amount of dry ice and ship by overnight courier. Formalin-fixed paraffin-embedded (FFPE) tissue block and FFPE tissue scrolls can be transported at room temperature.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

This test is a targeted RT-PCR analysis used to confirm the presence of a specific gene fusion (translocation) in a tumor sample that was previously identified by a research testing or by testing performed by another clinical laboratory. If a gene fusion is detected by this RT-PCR assay, a Sanger sequencing of PCR product will be performed to confirm the presence of gene fusion in the submitted sample.

This test is only available as a CONFIRMATORY TEST and only offered to patients who have a known gene fusion detected by previous research or clinical testing. If patient does not have a previously detected gene fusion, then this test cannot be ordered and sample will be rejected.

Please submit a copy of the previous tumor fusion test result, if available.

This test is a qualitative test that can test for the presence or absence of gene fusion previously identified in the patient. This test is not a qualitative test, will not be able to report what % of the sample harbors the gene fusion, and is not a test for Minimal Residual Disease (MRD).